You are here
SOYMEDS INC
UEI: GNJEJVHA9Q83
# of Employees: N/A
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: Yes
Award Charts
Award Listing
-
Oral autoantigen therapy for the treatment of Multiple Sclerosis
Amount: $583,553.00AbstractMultiple Sclerosis affects millions of people worldwide and while the past decade has seen a wave of disease-modifying drugs and immunomodulating therapies approved by the FDA, these drugs are ...
SBIRPhase I2021Department of Health and Human Services National Institutes of Health -
Platform for practical delivery of oral autoantigens as co therapies for neurological disease
Amount: $1,044,085.00ABSTRACT The difficulties for creating an efficacious oral autoantigen therapy are basically twofold practicality and efficacy Practically most protein autoantigens will be expensive to manufactur ...
SBIRPhase II2016Department of Health and Human Services National Institutes of Health -
Improved diagnostic and monitoring assays for thyroid cancer
Amount: $1,175,307.00DESCRIPTION provided by applicant Thyroid cancer is the most common type of endocrine malignancy New thyroid cancers patients are identified daily and most patients live for decades following dia ...
SBIRPhase II2013Department of Health and Human Services National Institutes of Health -
Improved diagnostic and monitoring assays for thyroid cancer
Amount: $216,221.00DESCRIPTION (provided by applicant): Thyroglobulin levels in the sera of thyroid cancer patients are routinely quantified using various agency-approved (e.g. FDA) immunoassays. Physicians frequently o ...
SBIRPhase I2010Department of Health and Human Services National Institutes of Health -
Novel therapy for treating Multiple Sclerosis
Amount: $239,720.00DESCRIPTION (provided by applicant): A variety of therapies have been attempted to treat Multiple Sclerosis. Such experimental therapies have included the administration of myelin basic protein, admin ...
SBIRPhase I2009Department of Health and Human Services National Institutes of Health -
A Novel Therapy for Staphylococcal Enterotoxin B Poisoning
Amount: $877,379.00DESCRIPTION (provided by applicant): Staphylococcus aureus is a significant human pathogen which can produce a variety of toxins, including the exotoxin, staphylococcal enterotoxin B (SEB). SEB is hig ...
STTRPhase II2009Department of Health and Human Services National Institutes of Health -
A Novel Therapy for Staphyloccocal Enterotoxin B poisoning
Amount: $200,970.00DESCRIPTION (provided by applicant): Edible vaccines have received much attention since, in theory, they represent a source of vaccine that would stimulate mucosal immune responses, be cost-effective ...
STTRPhase I2007Department of Health and Human Services National Institutes of Health